Therapeutic drug monitoring of antibiotics for methicillin-resistant Staphylococcus aureus infections: an updated narrative review for clinicians

Valentina Galfo,Giusy Tiseo,Niccolò Riccardi,Marco Falcone

DOI: https://doi.org/10.1016/j.cmi.2024.08.021

2024-08-27

Abstract:Background: Infections caused by methicillin-resistant Staphylococcus aureus (MRSA) are associated with high mortality rates. Optimal antibiotic dosage plays a crucial role in reducing MRSA burden; thus, the use of therapeutic drug monitoring (TDM) in the clinical practice, especially of new drugs such as ceftobiprole, ceftaroline, dalbavancin and oritavancin, should be implemented. Objectives: We aim to examine and summarize the available evidence about TDM of anti-MRSA molecules, with a focus on pneumonia, endocarditis and vascular infections, and bone and joint infections. Sources: We applied "therapeutic drug monitoring" and "Staphylococcus aureus" as search terms in PubMed, considering a time frame of 24 years (2001-2024). Articles in English language, non-duplicated, evaluating antibiotic therapeutic target and role of TDM were included in the study. Content: In this review, available data for therapeutic target and TDM were critically analyzed and summarized and suggestions about the use of old and new anti-MRSA antibiotics were provided, focusing on optimal dosages, tissue penetration according to infection types and toxicity. Limitations to the widespread use of TDM in the clinical practice were discussed. Implications: The use of TDM may play an important role for the optimal management of patients with MRSA infections and may impact on patient outcomes by increasing efficacy and reducing the risk of adverse events. TDM may be implemented in clinical practice, however several limitations such as the wide variability in the methodology and the need for skilled personnel need to be considered.